News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...

U.S. drugmaker Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharmaceuticals to develop and ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical ...

Merck announced a weight loss drug deal Wednesday with China-based Hansoh worth up to $2 billion for the pill code-named ...

Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's ...

U.S. drugmaker Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharmaceuticals to develop and ...

Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a ...

Viking Therapeutics (NASDAQ:VKTX) and Structure Therapeutics (NASDAQ:GPCR) were among notable decliners on Wednesday after ...

The Hansoh deal will let Merck compete in the crowded oral GLP-1 space alongside fellow pharma giants Eli Lilly, Novo Nordisk ...

Merck (MRK) and Hansoh Pharma, a Chinese biopharmaceutical company, announced that they have entered into an exclusive global license agreement ...

Merck & Co. is licensing a potential oral obesity drug from Hansoh Pharma in a deal potentially worth more than $2 billion to the Chinese biopharmaceutical company.

Merck & Company Inc (NYSE:MRK) shares are trading higher. The company on Wednesday announced a GLP-1 agreement with Chinese ...